Ampa One Collaborating With Wave Neuroscience - Nov 10

The Story

Ampa, the neurotechnology company behind Ampa One, said in a Nov. 10, 2026 release from PALO ALTO, Calif. that it will integrate Wave Neuroscience's EEG-based MeRT software so clinics can run MeRT treatment prescriptions on Ampa One's portable, subscription-based transcranial magnetic stimulation system.

Why It Matters For Your Portfolio

• Commercial Expansion: The integration gives clinics the ability to run Wave Neuroscience's MeRT software on Ampa One, which could speed device adoption across outpatient settings and broaden Ampa's addressable market.
• Subscription Model: Ampa One is described as subscription-based, which could translate to recurring revenue if clinic uptake follows, though no pricing or revenue figures were disclosed in the release.
• Clinical Access: Enabling MeRT on a portable TMS system may lower logistical barriers for clinics, potentially increasing procedure volume and service revenue over time.
• Information Gap: The Nov. 10, 2026 announcement does not include pricing, revenue projections, or rollout timelines, so near-term financial impact is uncertain and will depend on adoption rates and commercial execution.

The Trade

Growth and health-technology investors should follow adoption signals and any commercial terms the companies disclose, while traders may watch for follow-up announcements that clarify pricing or clinic partnerships. Watch for additional company releases, clinic rollout news, and any disclosures on subscription pricing or expected revenue impacts to gauge momentum. Will clinics move quickly to adopt MeRT on a portable TMS platform? That adoption pace will determine how meaningful this partnership becomes for commercial results.